Portal:CPTAC/Hallmark/Proliferative
From WikiPathways
(Difference between revisions)
(added pathway) |
(added pathway) |
||
| Line 14: | Line 14: | ||
*[[Pathway:WP4553]] FBXL10 enhancement of MAP/ERK signaling in diffuse large B-cell lymphoma | *[[Pathway:WP4553]] FBXL10 enhancement of MAP/ERK signaling in diffuse large B-cell lymphoma | ||
*[[Pathway:WP4566]] Translation inhibitors in chronically activated PDGFRA cells | *[[Pathway:WP4566]] Translation inhibitors in chronically activated PDGFRA cells | ||
| + | *[[Pathway:WP4541]] Hippo-Merlin Signaling Dysregulation | ||
Revision as of 18:17, 10 October 2019
The normal control of cell growth and division in cells is governed by careful control and release of growth-promoting signals, but in cancer cells this control is deregulated. Signaling through growth factors via the tyrosine kinase domains of cell-surface receptors, trigger progression through the cell cycle and other pathways. (Adapted from Hallmarks of cancer: the next generation, Hanahan and Weinberg, Cell 2011)
- Pathway:WP3972 PDGFR-beta pathway
- Pathway:WP673 ErbB Signaling Pathway
- Pathway:WP581 EPO Receptor Signaling
- Pathway:WP382 MAPK Signaling Pathway
- Pathway:WP4223 Ras Signaling
- Pathway:WP2828 Bladder Cancer
- Pathway:WP4205 MET in type 1 papillary renal cell carcinoma
- Pathway:WP4255 Non-small cell lung cancer
- Pathway:WP4263 Pancreatic adenocarcinoma pathway
- Pathway:WP4155 Endometrial cancer
- Pathway:WP313 Signaling of Hepatocyte Growth Factor Receptor
- Pathway:WP4553 FBXL10 enhancement of MAP/ERK signaling in diffuse large B-cell lymphoma
- Pathway:WP4566 Translation inhibitors in chronically activated PDGFRA cells
- Pathway:WP4541 Hippo-Merlin Signaling Dysregulation
